What diagnostic evaluation and management should be pursued for a 37‑year‑old man with 18‑pound unintentional weight loss over 15 months, an 11‑month history of epigastric pain that worsens on an empty stomach, previously treated Helicobacter pylori infection, failure of proton‑pump inhibitor therapy, fatigue, intermittent leg cramps, loose foul‑smelling stools, halitosis, cholecystectomy two months ago, and elevated hemoglobin A1c and vitamin D insufficiency (30.6 ng/mL)?

Diagnostic Evaluation and Management for Suspected Exocrine Pancreatic Insufficiency

This patient's constellation of symptoms—significant unintentional weight loss, loose foul-smelling stools, fat-soluble vitamin deficiency, elevated A1c, and PPI-refractory epigastric pain—strongly suggests exocrine pancreatic insufficiency (EPI), and you should immediately order a fecal elastase test on a semi-solid or solid stool specimen as the initial diagnostic test. 1

Immediate Diagnostic Workup

Primary Testing for EPI

• Fecal elastase-1 (FE-1) is the most appropriate initial test and must be performed on a semi-solid or solid stool specimen (not liquid diarrhea) 1
• A fecal elastase level <100 mg/g of stool provides good evidence of EPI, while levels of 100–200 mg/g are indeterminate 1
• This test can be performed while the patient is on any current medications 1

Cross-Sectional Imaging

• CT scan or MRI of the abdomen/pancreas should be obtained to evaluate for underlying pancreatic pathology (chronic pancreatitis, pancreatic cancer, or other structural abnormalities), though these cannot directly diagnose EPI 1
• This is critical given the patient's age, weight loss, and diabetes risk factors 1

Additional Laboratory Testing

• Complete blood count, comprehensive metabolic panel, albumin, prealbumin to assess nutritional status 2, 3
• Fat-soluble vitamin levels (A, D, E, K) to document deficiencies beyond the known vitamin D insufficiency 1
• Vitamin B12, folate, magnesium, zinc, selenium levels 3, 1
• Hemoglobin A1c (already elevated—this supports EPI as longstanding diabetes is a moderate-risk condition for EPI) 1
• Fecal occult blood testing to screen for malignancy 2, 4

Endoscopic Evaluation

• Upper endoscopy (EGD) with gastric and duodenal biopsies is indicated given PPI failure, persistent epigastric pain, and weight loss to exclude peptic ulcer disease, gastric malignancy, celiac disease, or other duodenal pathology 2, 5, 6
• Confirm H. pylori eradication status with gastric biopsies, as treatment failure occurs and reinfection is possible 6, 7

Clinical Reasoning

This patient meets multiple criteria for EPI suspicion:

High-risk features present: 1

• Longstanding diabetes mellitus (elevated A1c) is a moderate-risk condition for EPI
• Recent cholecystectomy (previous abdominal surgery)

Classic EPI symptoms: 1, 2

• Steatorrhea (loose, foul-smelling stools indicating fat malabsorption)
• Significant unintentional weight loss (18 pounds over 15 months)
• Fat-soluble vitamin deficiency (vitamin D insufficiency despite supplementation to 30.6 ng/mL)
• Bloating and excessive flatulence (implied by foul-smelling stools)
• Fatigue and muscle cramps (suggesting protein-calorie malnutrition and electrolyte abnormalities)

The epigastric pain worsening on an empty stomach, combined with treated H. pylori and PPI failure, raises concern for either recurrent/persistent H. pylori infection, peptic ulcer disease, or underlying pancreatic pathology causing both pain and EPI 5, 6.

Immediate Management

If EPI is Confirmed (FE-1 <100 mg/g)

Initiate pancreatic enzyme replacement therapy (PERT) immediately as untreated EPI results in complications from fat malabsorption and malnutrition with negative impact on quality of life and increased mortality 1

PERT Dosing: 1

• Start with at least 40,000 USP units of lipase with each meal and 20,000 USP units with snacks
• Take PERT during the meal (not before or after) to maximize mixing with food
• Adjust dosage based on meal size and fat content
• All FDA-approved formulations are porcine-derived and equally effective at equivalent doses

Adjunctive Acid Suppression: 1

• Continue or add PPI or H2-receptor antagonist therapy, as acid suppression enhances PERT efficacy (particularly important with non-enteric-coated preparations)

Nutritional Supplementation: 1

• Routine supplementation of fat-soluble vitamins (A, D, E, K) is appropriate
• Monitor and replace other identified deficiencies (B12, magnesium, zinc, selenium)
• Dietary modifications: low-moderate fat diet with frequent smaller meals; avoid very-low-fat diets

Baseline Assessments: 1

• Document BMI, quality-of-life measures
• Baseline DEXA scan for bone density (repeat every 1–2 years given risk of metabolic bone disease)
• Handgrip strength and muscle mass assessment

Monitoring Treatment Response

Measures of successful PERT treatment include: 1

• Reduction in steatorrhea and associated GI symptoms
• Weight gain, increased muscle mass and function
• Improvement in fat-soluble vitamin levels
• Stable patients should be reassessed at least annually

Critical Pitfalls to Avoid

1. Do not rely on therapeutic trial of pancreatic enzymes for diagnosis—response to empiric PERT is unreliable for confirming EPI 1

2. Do not perform fecal elastase on liquid stool—it must be semi-solid or solid for accurate results 1

3. Do not assume H. pylori is eradicated—treatment failure rates are significant, and reconfirmation with biopsy during endoscopy is warranted given persistent symptoms 7, 8

4. Do not overlook malignancy—unintentional weight loss in a 37-year-old warrants thorough evaluation for pancreatic cancer, gastric cancer, or other malignancies 9, 4

5. Do not forget to address the elevated A1c—coordinate care with endocrinology as diabetes management is essential in EPI patients 1

If Initial Workup is Negative

If fecal elastase is normal (>200 mg/g) and imaging/endoscopy are unremarkable, consider alternative diagnoses:

• Celiac disease (obtain duodenal biopsies during EGD and celiac serologies) 2
• Small intestinal bacterial overgrowth (consider breath testing)
• Microscopic colitis (requires colonic biopsies) 2
• Inflammatory bowel disease (particularly Crohn's disease affecting small bowel) 10

Up to 25% of patients with unintentional weight loss have no identifiable cause after comprehensive workup, warranting close 3–6 month follow-up 9, 4.